rhinitis%20-%20nonallergic
RHINITIS - NONALLERGIC
Nonallergic rhinitis is the inflammation of the nasal lining membranes without any immunoglobulin E mediation, as documented by allergen skin testing.
Major signs and symptoms include nasal itching, watery rhinorrhea, nasal obstruction/congestion, sneezing and postnasal drainage.
Symptoms can reverse spontaneously with or without treatment.

Rhinitis - Nonallergic Drug Information

Drug Information

Indication: Prophylaxis & chronic treatment of asthma in adults & childn ≥12 mth. Relief of daytime & night...

Indication: Allegic conditions including hay fever, urticaria, angioedema, vasomotor rhinitis, allergic eczema, atopic &am...

Indication: Allergic conditions including hay fever, urticaria, angioedema, vasomotor rhinitis, allergic eczema, atopic &a...

Indication: Symptomatic treatment of seasonal or perennial rhinitis in adults & childn ≥3 yr & acute rhinosinus...

Indication: Relief of nasal congestion in acute colds, paranasal sinusitis & otitis media.

Indication: Symptomatic relief of nasal & resp congestion, common cold, acute sinusitis, allergic rhinitis, vasomotor ...

Became
carbinoxamine maleate + pseudoephedrine hydrochlor...

Indication: Symptomatic relief of seasonal & allergic rhinitis, vasomotor rhinitis.

Indication: Prophylaxis & treatment of perennial & seasonal allergic rhinitis & vasomotor rhinitis.

Indication: Prevention & treatment of seasonal & perennial allergic rhinitis & vasomotor rhinitis.

Indication: Seasonal & perennial allergic rhinitis. Treatment & prevention of nasal polyps.

2  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 02 Dec 2020

People with HIV (PWH) who are hospitalized due to COVID-19 may have an increased mortality risk, according to a study from the UK.

21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Pearl Toh, 19 Dec 2020
With the release of the latest interim efficacy results for ChAdOx1 nCoV-19, the adenovirus-vectored vaccine against COVID-19 is inching a step closer towards regulatory approval — and eventually, widespread use that will hopefully put an end to the relentless carnage by the pandemic.
Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.